Cannabis

Formulation technology improving CBD uptake bought out

20-Feb-2020 By Vassia Barba

Bioavailability of water insoluble compounds, such as CBD, enhanced up to 15 times with the technology of Solmic, leading to its acquisition by Betterlife.

Sanofi in manufacturing deal for cannabinoid overdose treatment

01-Aug-2019 By Vassia Barba

Sanofi to manufacture and commercialize Opiant’s investigational treatment for acute cannabinoid overdose, which could become the first treatment for the condition.

Lonza enters a collaborative agreement with Auxly for capsule formulation

01-Jul-2019 By Maggie Lynch

Lonza will supply Auxly with materials and proprietary manufacturing equipment for capsule filling and sealing through collaborative agreement.

GW: Inventory and capacity set for ‘even the most aggressive of demand forecast’

28-Nov-2018 By Flora Southey

GW Pharma has told investors its capacity is “more than sufficient” to meet launch requirements in Europe next year, where the firm’s CBD medicine Epidiolex is under review.

Axim expands IP with cannabinoid suppository patent

01-Nov-2018 By Flora Southey

Axim predicts high demand from patients with symptoms and conditions that prevent swallowing.

Axim Biotech ‘closes GMP circle’ with manufacturing license for cannabinoids

16-Oct-2018 By Flora Southey

The Dutch Ministry of Health has granted Axim Biotech a manufacturing license to produce cannabis-derived candidates for clinical trials.

Johnson Matthey offers new synthetic method for ‘ultra-pure’ CBD

26-Sep-2018 By Flora Southey

The synthetic process produces a crystalline powder that can be particle size-adjusted for formulation requirements, says JM.

Has Big Pharma’s ‘inevitable entrance’ into the cannabis space arrived?

03-Sep-2018 By Flora Southey

Pfizer, GW Pharma, Merck & Co, and Sanofi-Aventis are among the leading cannabis patent holders in Canada, says report.

Lexaira Bioscience demonstrates high bioavailability in CBD platform

14-Aug-2018 By Maggie Lynch

Lexaira Bioscience says its DehydraTECH platform has demonstrated significant improvements to the bioavailability of cannabinoids, and could be applied to other pharmaceuticals.

GW prepping for mid-2018 CBD epilepsy candidate approval in US

05-Dec-2017 By Dan Stanton

Cannabinoid firm GW Pharmaceuticals says it is “inspection ready” as it prepares for potential US approval of its epilepsy candidate Epidiolex (cannabidiol or CBD).

Mexico legalizes medical marijuana: a boon for pharma?

28-Jun-2017 By Flora Southey

Mexican president Pena Nieto has legalised the cultivation, production and use of cannabis products with less than 1% THC for medical uses in Mexico.

Cure & cancer: cannabis molecule blend research

12-Jun-2017 By Flora Southey

Cure Pharmaceutical has entered into a strategic collaboration to test and develop potential cancer therapeutics utilising a blend of the cannabis plant-derived terpenes. 

Opioid API firm Noramco moves into cannabinoids

08-Mar-2017 By Gareth Macdonald

Noramco has added cannabinoids to its portfolio of opioid APIs.

Nemus hires Catalent to formulate second chemo-induced nausea drug

06-Mar-2017 By Gareth Macdonald

Catalent Pharma Solutions has been hired to formulate Nemus Bioscience’s synthetic cannabinoid based chemotherapy induced nausea drug.

Tilray begins shipping medical marijuana to more countries

20-Feb-2017 By Dani Bancroft

Medical marijuana developer Tilray has begun shipping to overseas patients and trial sites outside Canada after partnering with local distributors to comply with regional regulations.